C9ORF116 anticorps

N° du produit ABIN7246424

Détail du produit anti-C9ORF116 anticorps

Antigène: C9ORF116 (Chromosome 9 Open Reading Frame 116 (C9ORF116))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp C9ORF116 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC)

Attributs du produit: Polyclonal Antibody

Purification: Antigen affinity purification

Immunogène: Fusion protein of human C9orf116

Isotype: IgG

Information d'application

Indications d'application: IHC 1:50-1:300, ELISA 1:5000-1:10000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.96 mg/mL

Buffer: PBS with 0.05 % Sodium azide and 40 % Glycerol, pH 7.4

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur C9ORF116

Antigène: C9ORF116 (Chromosome 9 Open Reading Frame 116 (C9ORF116))

Autre désignation: C9orf116 (C9ORF116 Produits)

Synonymes: anticorps PIERCE1, anticorps RbEST47, anticorps Rbest47, anticorps chromosome 9 open reading frame 116, anticorps RIKEN cDNA 1700007K13 gene, anticorps chromosome ssa24 open reading frame, human C9orf116, anticorps chromosome 11 open reading frame, human C9orf116, anticorps C9orf116, anticorps 1700007K13Rik, anticorps cssa24h9orf116, anticorps C11H9orf116

Sujet: C9orf116, also known as PIERCE1. PIERCE1 is an important p53 target gene contributing to normal DNA damage response and may play crucial roles in maintaining genomic integrity against genotoxic stresses, including UVC irradiation. PIERCE1 exists as two alternatively spliced isoforms and is predominantly expressed in human small cell lung cancer. PIERCE1 knockdown induces down-regulation of proapoptotic genes including Ei24, Apaf1 and PTEN, suggesting that PIERCE1 is a proapoptotic gene. It is helpful for in-depth understanding of p53 pathways and the design of new cancer therapies.

UniProt: Q5BN46